Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic levornidazole phosphate disodium for prevention of surgical site infection after digestive tract surgery
ChiCTR2500095849Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levornidazole disodium phosphate in surgical site infection (SSI) (4 cohorts), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Incidence of surgical site infection during hospitalization and within 30 days after surgery. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
levornidazole disodium phosphate
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on ChiCTR2500095849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095849.